Mittwoch, 14. April 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone Compared to HD Cytarabine and Mitoxantrone and Control Sub-groups: MEC and FLAG in Older Patients With R/R AML

Rekrutierend

NCT-Nummer:
NCT03504410

Studienbeginn:
November 2018

Letztes Update:
20.07.2020

Wirkstoff:
CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine, Fludarabine, Cytarabine, Filgrastim

Indikation (Clinical Trials):
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Rafael Pharmaceuticals Inc.

Collaborator:
-

Studienleiter

Jorge Eduardo Cortes, MD
Principal Investigator
Augusta University

Kontakt

Studienlocations
(3 von 60)

Klinikum Frankfurt Hoechst
65929 Frankfurt
(Hessen)
GermanyRekrutierend» Google-Maps
UniversitatsklinikumUKSH Kiel
24105 Kiel
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Universitatsklinikum Marburg
35033 Marburg
(Hessen)
GermanyRekrutierend» Google-Maps
Robert-Bosch- Krankenhaus
70376 Stuttgart
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Honor Health Research Institute
85258 Scottsdale
United StatesRekrutierend» Google-Maps
Chao Family Comprehensive Cancer Center (University of California Irvine)
92868 Orange
United StatesRekrutierend» Google-Maps
California Pacific Medical Center
94115 San Francisco
United StatesRekrutierend» Google-Maps
Northwestern Memorial Hospital
60611 Chicago
United StatesRekrutierend» Google-Maps
Loyola University Medical Center
60153 Maywood
United StatesRekrutierend» Google-Maps
University of Iowa-Holden Cancer Care Center
52242 Iowa City
United StatesRekrutierend» Google-Maps
University of Kentucky
40436 Lexington
United StatesRekrutierend» Google-Maps
Norton Cancer Institute
40207 Louisville
United StatesRekrutierend» Google-Maps
Atlantic Health System
07960 Morristown
United StatesRekrutierend» Google-Maps
Rutgers Cancer Institute of New Jersey
08901 New Brunswick
United StatesRekrutierend» Google-Maps
Stony Brook University Hospital
11794 Long Island City
United StatesRekrutierend» Google-Maps
Memorial Sloan Kettering Cancer Center
10065 New York
United StatesRekrutierend» Google-Maps
Wake Forest Baptist Health
27157 Winston-Salem
United StatesRekrutierend» Google-Maps
University of Cincinnati
45219 Cincinnati
United StatesRekrutierend» Google-Maps
Oregon Health & Science University
97239 Portland
United StatesRekrutierend» Google-Maps
Texas Oncology - Baylor Charles A. Sammons Cancer Center
75246 Dallas
United StatesRekrutierend» Google-Maps
University of Texas - Southwestern Medical Center
75390 Dallas
United StatesRekrutierend» Google-Maps
MD Andrson Cancer Center
77030 Houston
United StatesRekrutierend» Google-Maps
University of Virginia
22908 Charlottesville
United StatesRekrutierend» Google-Maps
Border Medical Oncology Research Unit
2640 Albury
AustraliaRekrutierend» Google-Maps
Calvary Mater Newcastle Hospital
2298 Waratah
AustraliaRekrutierend» Google-Maps
Universitätsklinik für Innere Medizin
8036 Graz
AustriaRekrutierend» Google-Maps
Paracelsus Medical University
5020 Salzburg
AustriaRekrutierend» Google-Maps
Clinique Universitaire St Luc
1200 Brussels
BelgiumRekrutierend» Google-Maps
Centre Hospitalier de Versailles - Hôpital André Mignot
78157 Le Chesnay
FranceRekrutierend» Google-Maps
Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris
9300 Bobigny
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire Grenoble Hopital Michalon
38043 Grenoble Cedex 9
FranceRekrutierend» Google-Maps
Centre hospitalier Lyon Sud
69495 Pierre-Bénite
FranceRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Zespół Szpitali Miejskich w Chorzowie
41500 Chorzów
PolandRekrutierend» Google-Maps
Uniwersyteckie Centrum Kliniczne Klinika Hematologii i Transplantologii
80211 Gdańsk
PolandRekrutierend» Google-Maps
Katedra i Klinika Hematologii
50556 Wrocław
PolandRekrutierend» Google-Maps
Institut Catala d'Oncologia (ICO) - Hospital Universitari Germans Trias i Pujol
08916 Badalona
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen de la Victoria
29010 Málaga
SpainRekrutierend» Google-Maps
Hospital Son ESPASES
07120 Palma De Mallorca
SpainRekrutierend» Google-Maps
Hospital Clínico Universitario de Salamanca
37007 Salamanca
SpainRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

A Phase III study to evaluate the safety and efficacy of CPI-613® (devimistat) in combination with High Dose Cytarabine and Mitoxantrone in comparison with high dose Cytarabine and Mitoxantrone and control sub-groups: combination of Mitoxantrone, Etoposide and Cytarabine (MEC) and combination of Fludarabine, Cytarabine, and Filgrastim (FLAG) in older patients with relapsed/refractory Acute Myeloid Leukemia. CPI-613® (devimistat) targets the altered energy metabolism and processes for production of ATP and essential bio-intermediates unique to and characteristic of most cancer cell types. The addition of CPI-613® (devimistat) to high dose cytarabine and mitoxantrone (CHAM) will improve the complete remission (CR) rate in patients 50 years or older with relapsed or refractory AML when compared to HAM alone or other control sub groups.

Ein-/Ausschlusskriterien

INCLUSION CRITERIA:

1. Patient has provided an informed consent prior to initiation of any study specific activities/procedures

2. Males and females age ≥ 50 years must have histologically documented AML that is relapsed from, or refractory to, prior standard therapies

3. Refractory is defined as failure to achieve CR or CRi following:

1. At least one cycle of any anthracycline, cytarabine or fludarabine containing induction regimen or persistence of disease on a nadir marrow following at least one cycle of any anthracycline, cytarabine or fludarabine containing induction regimen

2. Persistent disease after at least 2 cycles of a hypomethylating agent (azacytidine or decitabine) with or without venetoclax

4. Relapse is defined as development of recurrent AML (as described by Döhner et al, 2017)6 after CR or CRi has been achieved with a prior chemotherapy or after disease progression on a hypomethylating agent with or without venetoclax

5. ECOG PS 0-2

6. Expected survival greater than 3 months

7. Women of child-bearing potential (i.e. women who are pre-menopausal or < 2 years post menopausal or not surgically sterile) must practice a highly effective method of birth control consistent with local regulations regarding the use of birth control methods. Examples: use of oral, injected or implanted hormonal methods of contraception; placement of an intra uterine device (IUD) or intrauterine system (IUS); male partner sterilization (the vasectomized partner should be the sole partner for that subject); true abstinence during and for 6 months after the last administered dose of CHAM or HAM therapy and control sub-groups (MEC and FLAG), and must have a negative serum pregnancy test within 1 week prior to treatment initiation and at 1st day of each cycle and at the end of systemic exposure. (Note: pregnant patients are excluded because the effects of CPI-613® (devimistat) on a fetus are unknown)

8. Fertile men who are sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository during the study period and up to 6 months after completion of the study screening, unless documentation of infertility exists

9. Good state of mental health, ability to understand and willingness to sign the informed consent form (ICF)

10. No radiotherapy, treatment with cytotoxic chemotherapy, treatment with biologic agents or any anti-cancer therapy for R/R AML within the 1 week prior to treatment with CPI-613® (devimistat). Hydroxyurea and/or venetoclax and oral tyrosine kinase (FLT3) or Isocitrate Dehydrogenase 1 and 2 (IDH1/2), BCL-2 or hedgehog inhibitors being used with Grade ≤ 2 toxicity can be taken until the day prior to starting of CHAM or HAM therapy or control sub-groups (MEC and FLAG). Previous exposure to a hypomethylating agent either alone or in combination with Isocitrate Dehydrogenase 1 and 2 (IDH1/2), BCL-2 or hedgehog inhibitors are allowed until the day prior to starting of CHAM or HAM therapy and control sub-groups (MEC and FLAG). Patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities with the exception of alopecia (returned to baseline status as noted before most recent treatment). Patients with persisting, non-hematologic, non-infectious toxicities from prior treatment Grade ≤ 2 are eligible but must be documented as such

11. Laboratory values ≤ 2 weeks before dosing must be:

- Adequate hepatic function (aspartate aminotransferase/serum glutamic-oxaloacetic transaminase [AST/SGOT] ≤ 5 x upper limit of normal [ULN], alanine aminotransferase/serum glutamic oxaloacetic transaminase [ALT/SGPT] ≤ 5 × ULN, bilirubin ≤ 1.5 × ULN)

- Adequate renal function (serum creatinine clearance ≥ 60 mL/min per CockCroft Gault formula)

- Adequate coagulation (International Normalized Ratio [INR] must be < 1.7 unless on vitamin k antagonist anticoagulation)

12. Left Ventricular Ejection Fraction (LVEF) by Transthoracic Echocardiogram (TTE) or Multigated Acquisition Scan (MUGA) or cardiac Magnetic Resonance Imaging (MRI), sufficient to safely administer mitoxantrone. Subjects must have an LVEF ≥ 45%

13. No marked baseline prolongation of QT/QTc interval (repeated exhibition of a QTc interval > 480 ms for both male and female patients)

14. No history of additional risk factors for torsade de pointes (e.g. clinically significant heart failure, hypokalemia, immediate family history of Long QT Syndrome)

15. Allow only patients who experienced relapse after 1 year from previous HiDAC treatment or who didn't receive HiDAC previously (Note: This inclusion applies only to South Korea)

EXCLUSION CRITERIA:

1. Patients who have received cytotoxic chemotherapy treatment for their current relapsed or refractory AML. (Treatment with hypomethylating agents (decitabine or azacytidine) either alone or in combination with venetoclax are allowed until the day prior to starting of CHAM or HAM therapy and control sub-groups (MEC and FLAG). Targeted therapies including FLT3 or IDH1/2 inhibitors and/or Hydrea and/or venetoclax are allowed. Targeted therapies and Hydrea may be taken until the day prior to starting CHAM or HAM therapy or control sub-groups (MEC and FLAG)

2. Vulnerable adult and patient whose health conditions does not allow them to give their consent

3. History or evidence of any other clinically significant disorder, condition or disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion

4. Patients with active Central Nervous System (CNS) involvement (leukemic infiltration, blast in the spinal fluid)

5. Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g. active peptic ulcer disease)

6. Female patients who are pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 6 months after the last dose of CHAM or HAM therapy or control sub-groups, MEC and FLAG (the teratogenic potential of CPI-613® (devimistat) is unknown). Female patients of childbearing potential with a positive pregnancy test assessed by a serum pregnancy test at Screening

7. Women of childbearing potential (i.e. women who are pre-menopausal or < 2 years postmenopausal or not surgically sterile) unwilling to practice a highly effective method of birth control consistent with local regulations regarding the use of birth control methods during treatment and for 6 months after completion of CHAM or HAM therapy or control sub-groups, MEC and FLAG for AML

8. Male patients with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for 6 months after completion of CHAM or HAM therapy or control sub-groups, MEC and FLAG

9. Male patients unwilling to abstain from donating sperm during treatment and for 6 months after completion of CHAM or HAM therapy or control sub-groups, MEC and FLAG with potential highest teratogenic risk

10. Known hypersensitivity to study treatment drugs or any of the excipient(s) contained in the drug formulation

11. Life expectancy less than 3 months

12. Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients

13. Unwilling or unable to follow protocol requirements

14. Patients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly)

15. Patients with any amount of clinically significant pericardial effusion that requires drainage.

16. Evidence of ongoing, uncontrolled bacterial, viral or fungal infection

17. Patients with known human immunodeficiency virus infection

18. History of other malignancy within the past 5 years, with the following exception(s):

1. Malignancy treated with curative intent and with no known active disease present for ≥ 5 years before enrolment and felt to be at low risk for recurrence by the treating physician

2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of recurrent or residual disease

3. Adequately treated cervical carcinoma in situ without evidence of disease

4. Prostate cancer Stage 1

19. Patients receiving any other standard or investigational treatment for AML, or any other investigational agent for any indication within the past 1 week prior to initiation of CPI-613® (devimistat) treatment (the use of Hydrea and/or venetoclax, oral tyrosine kinase inhibitors FLT3 or IDH 1/2 inhibitors are allowed until the day prior to starting CHAM or HAM therapy or control sub-groups, MEC and FLAG. Previous exposure to a hypomethylating agent either alone or in combination with venetoclax are allowed until the day prior to starting of CHAM or HAM therapy and control sub-groups (MEC and FLAG))

20. Patients who have received immunotherapy of any type within the past 1 week prior to initiation of CPI-613® (devimistat) treatment

21. Requirement for immediate palliative treatment of any kind including minor surgery

22. Patients who have received a chemotherapy regimen with autologous stem cell support (bone marrow transplantation) within 6 months of starting CHAM or HAM therapy or control sub-groups (MEC and FLAG)

23. Patients who have had allogenic bone marrow transplantation within the last 6 months. Patients who have had an allogenic transplant more than 6 months ago are eligible provided they have no graft vs host disease. (Note: Exclude only patients with active GVHD requiring therapy with immunosuppressive agents and not patients with stable GVHD not requiring immunosuppression.)

24. Cytarabine contraindications

- Hypersensitivity to the cytarabine or to any of the excipients of cytarabine injection

- Anemia, leucopenia and thrombocytopenia of non-malignant aetiology (e.g bone marrow aplasia); unless the clinician feels that such management offers the most hopeful alternative for the patient

- Degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation

25. Mitoxantrone contraindications

- Mitoxantrone Sterile Concentrate is contraindicated in patients who have demonstrated prior hypersensitivity to mitoxantrone hydrochloride, other anthracyclines or any of its components. Use in patients with profound bone marrow suppression is a relative contraindication depending on the clinical circumstances

- Mitoxantrone Sterile Concentrate should not be used during pregnancy or lactation

26. Strong CYP450 inducers should be prohibited

27. Etoposide contraindications

•. Contraindicated in patients with a history of a severe hypersensitivity reaction to etoposide products

28. Fludarabine contraindications

•. Contraindicated in those patients who are hypersensitive to this drug or its components

29. Filgrastim contraindications •. Contraindicated in patients with known hypersensitivity to E coli-derived proteins, Filgrastim, or any component of the product

Studien-Rationale

Primary outcome:

1. Complete Remission (CR) (Time Frame - 8 months):
Complete disappearance of all clinical evidence of disease



Secondary outcome:

1. Overall Survival (OS) (Time Frame - 12 months):
the duration from the date of randomization to the date of death from any cause

2. CR+CRh (Time Frame - 12 months):
Complete Remission + CR with partial hematological recovery (CRh)

Studien-Arme

  • Experimental: CPI-613 + HD Cytarabine and Mitoxantrone
    CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613 at 2,000 mg/m2/day from day 1 to 5. Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 2nd and 5th doses of Cytarabine.
  • Active Comparator: Control (HAM) and control sub-groups (MEC and FLAG)
    High Dose Cytarabine and Mitoxantrone Cytarabine at 1gm/m2 (5 doses), every 12 hours starting day 3. Mitoxantrone at 6gm/m2 (3 doses), everyday following the 1st, 3rd and 5th doses of Cytarabine. Mitoxantrone, Etoposide and Cytarabine Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6 Fludarabine, Cytarabine and Filgrastim Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5

Geprüfte Regime

  • CPI-613 + High Dose Cytarabine and Mitoxantrone (CPI-613, CHAM):
    CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
  • High Dose Cytarabine and Mitoxantrone (HAM):
    Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
  • Mitoxantrone, Etoposide and Cytarabine (MEC):
    Mitoxantrone, Etoposide and Cytarabine Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6
  • Fludarabine, Cytarabine, Filgrastim (FLAG):
    Fludarabine, Cytarabine and Filgrastim Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Erstes bundesweites Sommertreffen junger engagierter Krebspatienten
Erstes+bundesweites+Sommertreffen+junger+engagierter+Krebspatienten
© Frantab / fotolia.com

„Danke für den gemeinsamen Spirit. Möge er uns weiter beflügeln“, so ein Feedback zum ersten Sommertreffen junger Krebspatienten in Deutschland. Frauen und Männer aus der gesamten Bundesrepublik kamen vom 29. Juni bis 1. Juli 2018 das erste Mal in Lauterbach (Hessen) zu einem gemeinsamen Kennenlernen und Austausch zusammen. Die etwa 50 Teilnehmer engagieren sich in den TREFFPUNKTEN der Deutschen Stiftung...

Brustkrebs: Was Frauen über die Früherkennung wissen sollten – und welche Risikofaktoren existieren
Brustkrebs%3A+Was+Frauen+%C3%BCber+die+Fr%C3%BCherkennung+wissen+sollten+%E2%80%93+und+welche+Risikofaktoren+existieren
© serhiibobyk / Fotolia.com

Etwa jede achte Frau erkrankt hierzulande an Brustkrebs. Insgesamt betrifft dies 72.000 Neuerkrankungen pro Jahr. Obwohl Brustkrebs in erster Linie eine Erkrankung der Frau nach den Wechseljahren ist, können auch deutlich jüngere Frauen erkranken. Aber – für welche Frau macht welche Untersuchung in welchem Alter Sinn? Das Mammographie-Screening-Programm gilt für Frauen von 50 bis 69 Jahren. Was insbesondere Frauen...

Gesundheitsversorgung auf dem Land – weite Wege, lange Wartezeiten
Gesundheitsversorgung+auf+dem+Land+%E2%80%93+weite+Wege%2C+lange+Wartezeiten
Krebsinformationsdienst, DKFZ

Eine repräsentative Umfrage* vom Dezember 2017 hat gezeigt: Die medizinische Versorgung in ländlichen Regionen weist aus Sicht vieler Befragter Defizite auf. Bemängelt wurden lange Wartezeiten auf Arzttermine, weite Wege und weniger Informationsmöglichkeiten. Auch für Krebspatienten und ihre Angehörigen kann diese Situation belastend sein. Der Krebsinformationsdienst des Deutschen Krebsforschungszentrums ersetzt...